Table of Contents Author Guidelines Submit a Manuscript
PPAR Research
Volume 2010, Article ID 698730, 11 pages
http://dx.doi.org/10.1155/2010/698730
Review Article

PPARs in the Renal Regulation of Systemic Blood Pressure

Department of Regenerative Cardiology, Spanish National Cardiovascular Research Center (CNIC), 28029 Madrid, Spain

Received 23 September 2009; Revised 24 February 2010; Accepted 31 March 2010

Academic Editor: Tianxin Yang

Copyright © 2010 Tamás Rőszer and Mercedes Ricote. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. S. Heikkinen, J. Auwerx, and C. A. Argmann, “PPARγ in human and mouse physiology,” Biochimica et Biophysica Acta, vol. 1771, no. 8, pp. 999–1013, 2007. View at Publisher · View at Google Scholar · View at Scopus
  2. G. Medina-Gómez, S. Gray, and A. Vidal-Pluig, “Role of PPARs in the pathogenesis of the metabolic syndrome,” in The Metabolic Syndrome at the Beginning of the 21st Century, M. Serrano, J. F. Caro, R. Carraro, and J. A. Gutiérez Fuentes, Eds., pp. 264–265, Elsevier, Madrid, Spain, 2005. View at Google Scholar
  3. S. Z. Duan, C. Y. Ivashchenko, M. G. Usher, and R. M. Mortensen, “PPAR-γ in the cardiovascular system,” PPAR Research, vol. 2008, Article ID 745804, 10 pages, 2008. View at Publisher · View at Google Scholar
  4. Y. Takata, J. Liu, F. Yin et al., “PPARd-mediated antiinflammatory mechanisms inhibit angiotensin II-accelerated atherosclerosis,” Proceedings of the National Academy of Sciences of the United States of America, vol. 105, no. 11, pp. 4277–4282, 2008. View at Publisher · View at Google Scholar · View at Scopus
  5. A. Meirhaeghe and P. Amouyel, “Impact of genetic variation of PPARγ in humans,” Molecular Genetics and Metabolism, vol. 83, no. 1-2, pp. 93–102, 2004. View at Publisher · View at Google Scholar · View at Scopus
  6. M. Horiki, H. Ikegami, T. Fujisawa et al., “Association of Pro12Ala polymorphism of PPAR? gene with insulin resistance and related diseases,” Diabetes Research and Clinical Practice, vol. 66, pp. S63–S67, 2004. View at Publisher · View at Google Scholar · View at Scopus
  7. N. Wang, J. D. Symons, H. Zhang, Z. Jia, F. J. Gonzalez, and T. Yang, “Distinct functions of vascular endothelial and smooth muscle PPARγ in regulation of blood pressure and vascular tone,” Toxicologic Pathology, vol. 37, no. 1, pp. 21–27, 2009. View at Publisher · View at Google Scholar · View at Scopus
  8. P. Obih and A. Oyekan, “Regulation of blood pressure, natriuresis and renal thiazide/amiloride sensitivity in PPARα null mice,” Blood Pressure, vol. 17, no. 1, pp. 55–63, 2008. View at Publisher · View at Google Scholar · View at Scopus
  9. R. Komers and A. Vrána, “Thiazolidinediones—tools for the research of metabolic syndrome X,” Physiological Research, vol. 47, no. 4, pp. 215–225, 1998. View at Google Scholar · View at Scopus
  10. C. Yagil and Y. Yagil, “Peroxisome proliferator-activated receptor-α: friend or foe?” Hypertension, vol. 50, no. 5, pp. 847–850, 2007. View at Publisher · View at Google Scholar · View at Scopus
  11. J. J. Nolan, B. Ludvik, P. Beerdsen, M. Joyce, and J. Olefsky, “Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone,” The New England Journal of Medicine, vol. 331, no. 18, pp. 1188–1193, 1994. View at Publisher · View at Google Scholar · View at Scopus
  12. M. St John Sutton, M. Rendell, P. Dandona et al., “A comparison of the effects of rosiglitazone and glyburide on cardiovascular function and glycemic control in patients with type 2 diabetes,” Diabetes Care, vol. 25, no. 11, pp. 2058–2064, 2002. View at Google Scholar · View at Scopus
  13. S. Takai, D. Jin, M. Kimura et al., “Inhibition of vascular angiotensin-coverting enzyme by telmisartan via the peroxisome proliferator-activated receptor ? agonistic property in rats,” Hypertension Research, vol. 30, no. 12, pp. 1231–1237, 2007. View at Publisher · View at Google Scholar · View at Scopus
  14. H. Toba, S. Miki, T. Shimizu et al., “The direct antioxidative and anti-inflammatory effects of peroxisome proliferator-activated receptors ligands are associated with the inhibition of angiotensin converting enzyme expression in streptozotocin-induced diabetic rat aorta,” European Journal of Pharmacology, vol. 549, no. 1–3, pp. 124–132, 2006. View at Publisher · View at Google Scholar · View at Scopus
  15. M. J. Ryan, S. P. Didion, S. Mathur, F. M. Faraci, and C. D. Sigmund, “PPARγ agonist rosiglitazone improves vascular function and lowers blood pressure in hypertensive transgenic mice,” Hypertension, vol. 43, no. 3, pp. 661–666, 2004. View at Publisher · View at Google Scholar · View at Scopus
  16. K. Takeda, T. Ichiki, Y. Funakoshi, K. Ito, and A. Takeshita, “Downregulation of angiotensin II type 1 receptor by all-trans retinoic acid in vascular smooth muscle cells,” Hypertension, vol. 35, no. 1, pp. 297–302, 2000. View at Google Scholar · View at Scopus
  17. V. Haxsen, S. Adam-Stitah, E. Ritz, and J. Wagner, “Retinoids inhibit the actions of angiotensin II on vascular smooth muscle cells,” Circulation Research, vol. 88, no. 6, pp. 637–644, 2001. View at Google Scholar · View at Scopus
  18. E. R. Blasi, J. Heyen, M. Hemkens, A. McHarg, C. M. Ecelbarger, and S. Tiwari, “Effects of chronic PPAR-agonist treatment on cardiac structure and function, blood pressure, and kidney in healthy sprague-dawley rats,” PPAR Research, vol. 2009, Article ID 237865, 13 pages, 2009. View at Publisher · View at Google Scholar · View at Scopus
  19. K. M. Tordjman, C. F. Semenkovich, T. Coleman et al., “Absence of peroxisome proliferator-activated receptor-a abolishes hypertension and attenuates atherosclerosis in the Tsukuba hypertensive mouse,” Hypertension, vol. 50, no. 5, pp. 945–951, 2007. View at Publisher · View at Google Scholar · View at Scopus
  20. M. Hamblin, L. Chang, J. Zhang, and Y. E. Chen, “The role of peroxisome proliferator-activated receptor γ in blood pressure regulation,” Current Hypertension Reports, vol. 11, no. 4, pp. 239–245, 2009. View at Publisher · View at Google Scholar · View at Scopus
  21. T. D. Giles and G. E. Sander, “Effects of thiazolidinediones on blood pressure,” Current Hypertension Reports, vol. 9, no. 4, pp. 332–337, 2007. View at Publisher · View at Google Scholar · View at Scopus
  22. I. J. Jonkers, F. H. de Man, A. van der Laarse et al., “Bezafibrate reduces heart rate and blood pressure in patients with hypertriglyceridemia,” Journal of Hypertension, vol. 19, no. 4, pp. 749–755, 2001. View at Publisher · View at Google Scholar · View at Scopus
  23. M. C. Lansang, C. Coletti, S. Ahmed, M. S. Gordon, and N. K. Hollenberg, “Effects of the PPAR-γ agonist rosiglitazone on renal haemodynamics and the renin-angiotensin system in diabetes,” Journal of the Renin-Angiotensin-Aldosterone System, vol. 7, no. 3, pp. 175–180, 2006. View at Publisher · View at Google Scholar · View at Scopus
  24. Y. Shimamoto, K. Hirota, and A. Fukamizu, “Effect of peroxisome proliferator-activated receptor α on human angiotensinogen promoter,” International Journal of Molecular Medicine, vol. 13, no. 5, pp. 729–733, 2004. View at Google Scholar · View at Scopus
  25. H. Kobori, M. Nangaku, L. G. Navar, and A. Nishiyama, “The intrarenal renin-angiotensin systemml: from physiology to the pathobiology of hypertension and kidney disease,” Pharmacological Reviews, vol. 59, no. 3, pp. 251–287, 2007. View at Publisher · View at Google Scholar · View at Scopus
  26. L. Yvan-Charvet, F. Massiéra, N. Lamandé et al., “Deficiency of angiotensin type 2 receptor rescues obesity but not hypertension induced by overexpression of angiotensinogen in adipose tissue,” Endocrinology, vol. 150, no. 3, pp. 1421–1428, 2009. View at Google Scholar · View at Scopus
  27. H. Lu, C. M. Boustany-Kari, A. Daugherty, and L. A. Cassis, “Angiotensin II increases adipose angiotensinogen expression,” American Journal of Physiology, vol. 292, no. 5, pp. E1280–E1287, 2007. View at Publisher · View at Google Scholar · View at Scopus
  28. H. Lu, D. L. Rateri, D. L. Feldman et al., “Renin inhibition reduces hypercholesterolemia-induced atherosclerosis in mice,” Journal of Clinical Investigation, vol. 118, no. 3, pp. 984–993, 2008. View at Publisher · View at Google Scholar · View at Scopus
  29. M. Gupte, C. M. Boustany-Kari, K. Bharadwaj et al., “ACE2 is expressed in mouse adipocytes and regulated by a high-fat diet,” American Journal of Physiology, vol. 295, no. 3, pp. R781–R788, 2008. View at Publisher · View at Google Scholar · View at Scopus
  30. B. Gálvez-Prieto, J. Bolbrinker, P. Stucchi et al., “Comparative expression analysis of the renin—angiotensin system components between white and brown perivascular adipose tissue,” Journal of Endocrinology, vol. 197, no. 1, pp. 55–64, 2008. View at Publisher · View at Google Scholar · View at Scopus
  31. F. Sugiyama, S. Haraoka, T. Watanabe et al., “Acceleration of atherosclerotic lesions in transgenic mice with hypertension by the activated renin-angiotensin system,” Laboratory Investigation, vol. 76, no. 6, pp. 835–842, 1997. View at Google Scholar · View at Scopus
  32. N. Nishijo, F. Sugiyama, K. Kimoto et al., “Salt-sensitive aortic aneurysm and rupture in hypertensive transgenic mice that overproduce angiotensin II,” Laboratory Investigation, vol. 78, no. 9, pp. 1059–1066, 1998. View at Google Scholar · View at Scopus
  33. P. Bichu, R. Nistala, A. Khan, J. R. Sowers, and A. Whaley-Connell, “Angiotensin receptor blockers for the reduction of proteinuria in diabetic patients with overt nephropathy: results from the AMADEO study,” Vascular Health and Risk Management, vol. 5, pp. 129–140, 2009. View at Google Scholar · View at Scopus
  34. J. G. Robinson, “Should we use PPAR agonists to reduce cardiovascular risk?” PPAR Research, vol. 2008, Article ID 891425, 13 pages, 2008. View at Publisher · View at Google Scholar · View at Scopus
  35. S. Sena, I. R. Rasmussen, A. R. Wende et al., “Cardiac hypertrophy caused by peroxisome proliferator-activated receptor-? agonist treatment occurs independently of changes in myocardial insulin signaling,” Endocrinology, vol. 148, no. 12, pp. 6047–6053, 2007. View at Publisher · View at Google Scholar · View at Scopus
  36. M. Schupp, M. Clemenz, R. Gineste et al., “Molecular characterization of new selective peroxisome proliferator-activated receptor ? modulators with angiotensin receptor blocking activity,” Diabetes, vol. 54, no. 12, pp. 3442–3452, 2005. View at Publisher · View at Google Scholar · View at Scopus
  37. V. T. Todorov, M. Desch, N. Schmitt-Nilson, A. Todorova, and A. Kurtz, “Peroxisome proliferator-activated receptor-γ is involved in the control of renin gene expression,” Hypertension, vol. 50, no. 5, pp. 939–944, 2007. View at Publisher · View at Google Scholar · View at Scopus
  38. R. Di Nicolantonio, L. Lan, and A. Wilks, “Nucleotide variations in intron 1 of the renin gene of the spontaneously hypertensive rat,” Clinical and Experimental Hypertension, vol. 20, no. 1, pp. 27–40, 1998. View at Google Scholar · View at Scopus
  39. V. T. Todorov, M. Desch, T. Schubert, and A. Kurtz, “The Pal3 promoter sequence is critical for the regulation of human renin gene transcription by peroxisome proliferator-activated receptor-γ,” Endocrinology, vol. 149, no. 9, pp. 4647–4657, 2008. View at Publisher · View at Google Scholar · View at Scopus
  40. M. Desch, A. Schreiber, F. Schweda et al., “Increased renin production in mice with deletion of peroxisome proliferator-activated receptor-? in juxtaglomerular cells,” Hypertension, vol. 55, no. 3, pp. 660–666, 2010. View at Publisher · View at Google Scholar · View at Scopus
  41. D. Takahashi, K. Tamura, T. Ushikubo et al., “Relationship between hepatic angiotensinogen mRNA expression and plasma angiotensinogen in patients with chronic hepatitis,” Life Sciences, vol. 60, no. 18, pp. 1623–1633, 1997. View at Publisher · View at Google Scholar · View at Scopus
  42. L. J. Bloem, A. K. Manatunga, D. A. Tewksbury, and J. H. Pratt, “The serum angiotensinogen concentration and variants of the angiotensinogen gene in white and black children,” Journal of Clinical Investigation, vol. 95, no. 3, pp. 948–953, 1995. View at Google Scholar · View at Scopus
  43. N. Tomita, R. Morishita, J. Higaki et al., “Effect of angiotensinogen on blood pressure regulation in normotensive rats: application of a loss of function approach,” Journal of Hypertension, vol. 13, no. 12, pp. 1767–1774, 1995. View at Google Scholar · View at Scopus
  44. Y.-S. Tsai, H.-J. Kim, N. Takahashi et al., “Hypertension and abnormal fat distribution but not insulin resistance in mice with P465L PPAR?,” Journal of Clinical Investigation, vol. 114, no. 2, pp. 240–249, 2004. View at Publisher · View at Google Scholar · View at Scopus
  45. J. Rieusset, J. Auwerx, and H. Vidal, “Regulation of gene expression by activation of the peroxisome proliferator-activated receptor γ with rosiglitazone (BRL 49653) in human adipocytes,” Biochemical and Biophysical Research Communications, vol. 265, no. 1, pp. 265–271, 1999. View at Publisher · View at Google Scholar · View at Scopus
  46. T. Unger and M. Stoppelhaar, “Rationale for double renin-angiotensin-aldosterone system blockade,” American Journal of Cardiology, vol. 100, no. 3, pp. S25–S31, 2007. View at Publisher · View at Google Scholar · View at Scopus
  47. J. Song, H. Liu, H. W. Ressom, S. Tiwari, and C. M. Ecelbarger, “Chronic rosiglitazone therapy normalizes expression of ACE1, SCD1 and other genes in the kidney of obese zucker rats as determined by microarray analysis,” Experimental and Clinical Endocrinology and Diabetes, vol. 116, no. 6, pp. 315–325, 2008. View at Publisher · View at Google Scholar · View at Scopus
  48. S. Efrati, S. Berman, E. Ilgiyeav, Z. Averbukh, and J. Weissgarten, “PPAR-γ activation inhibits angiotensin II synthesis, apoptosis, and proliferation of mesangial cells from spontaneously hypertensive rats,” Nephron Experimental Nephrology, vol. 106, no. 4, pp. e107–e112, 2007. View at Publisher · View at Google Scholar · View at Scopus
  49. R. A. Sanchez, L. D. Masnatta, C. Pesiney, P. Fischer, and A. J. Ramirez, “Telmisartan improves insulin resistance in high renin nonmodulating salt-sensitive hypertensives,” Journal of Hypertension, vol. 26, no. 12, pp. 2393–2398, 2008. View at Google Scholar · View at Scopus
  50. S. Subramanian, M. A. DeRosa, C. Bernal-Mizrachi et al., “PPARa activation elevates blood pressure and does not correct glucocorticoid-induced insulin resistance in humans,” American Journal of Physiology, vol. 291, no. 6, pp. E1365–E1371, 2006. View at Publisher · View at Google Scholar · View at Scopus
  51. T. Tagami, H. Yamamoto, K. Moriyama et al., “A selective peroxisome proliferator-activated receptor-? modulator, telmisartan, binds to the receptor in a different fashion from thiazolidinediones,” Endocrinology, vol. 150, no. 2, pp. 862–870, 2009. View at Publisher · View at Google Scholar · View at Scopus
  52. M. Mazerska and M. Myśliwiec, “Telmisartan lowers albuminuria in type 2 diabetic patients treated with angiotensin enzyme inhibitors,” Advances in Medical Sciences, vol. 54, no. 1, pp. 37–40, 2009. View at Google Scholar · View at Scopus
  53. X. Liu, L. Lü, B.-B. Tao, and Y.-C. Zhu, “All-trans retinoic acid inhibits the increases in fibronectin and PAI-1 induced by TGF-β1 and Ang II in rat mesangial cells,” Acta Pharmacologica Sinica, vol. 29, no. 9, pp. 1035–1041, 2008. View at Publisher · View at Google Scholar · View at Scopus
  54. I. Imayama, T. Ichiki, K. Inanaga et al., “Telmisartan downregulates angiotensin II type 1 receptor through activation of peroxisome proliferator-activated receptor ?,” Cardiovascular Research, vol. 72, no. 1, pp. 184–190, 2006. View at Publisher · View at Google Scholar · View at Scopus
  55. P. Gosse, “A review of telmisartan in the treatment of hypertension: blood pressure control in the early morning hours,” Vascular Health and Risk Management, vol. 2, no. 3, pp. 195–201, 2006. View at Publisher · View at Google Scholar · View at Scopus
  56. N. Kobayashi, T. Ohno, K. Yoshida et al., “Cardioprotective mechanism of telmisartan via PPAR-?-eNOS pathway in dahl salt-sensitive hypertensive rats,” American Journal of Hypertension, vol. 21, no. 5, pp. 576–581, 2008. View at Publisher · View at Google Scholar · View at Scopus
  57. S. Yamagishi and M. Takeuchi, “Telmisartan is a promising cardiometabolic sartan due to its unique PPAR-γ-inducing property,” Medical Hypotheses, vol. 64, no. 3, pp. 476–478, 2005. View at Publisher · View at Google Scholar · View at Scopus
  58. J. A. Dormandy, B. Charbonnel, D. J. Eckland et al., “Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial in macroVascular Events): a randomised controlled trial,” The Lancet, vol. 366, no. 9493, pp. 1279–1289, 2005. View at Publisher · View at Google Scholar · View at Scopus
  59. T. Unger and M. Schupp, “Telmisartan: from lowering blood pressure to end-organ protection,” Future Cardiology, vol. 1, pp. 7–15, 2005. View at Google Scholar
  60. R. Rizza, R. Henry, and R. Kahn, “Commentary on the results and clinical implications of the PROactive study,” Diabetes Care, vol. 28, no. 12, pp. 2965–2967, 2005. View at Publisher · View at Google Scholar · View at Scopus
  61. M. Komajda, J. J. V. McMurray, H. Beck-Nielsen et al., “Heart failure events with rosiglitazone in type 2 diabetes: data from the RECORD clinical trial,” European Heart Journal, vol. 31, no. 7, pp. 824–831, 2010. View at Publisher · View at Google Scholar · View at Scopus
  62. J. N. Basile, “Antihypertensive therapy, new-onset diabetes, and cardiovascular disease,” International Journal of Clinical Practice, vol. 63, no. 4, pp. 656–666, 2009. View at Publisher · View at Google Scholar · View at Scopus
  63. S. Wakino, U. Kintscher, S. Kim et al., “Retinoids inhibit proliferation of human coronary smooth muscle cells by modulating cell cycle regulators,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 21, no. 5, pp. 746–751, 2001. View at Google Scholar · View at Scopus
  64. Q. N. Diep, F. Amiri, R. M. Touyz et al., “PPARa activator effects on Ang II-induced vascular oxidative stress and inflammation,” Hypertension, vol. 40, no. 6, pp. 866–871, 2002. View at Publisher · View at Google Scholar · View at Scopus
  65. T. Nakamura, K. Kawachi, Y. Saito et al., “Effects of ARB or ACE-inhibitor administration on plasma levels of aldosterone and adiponectin in hypertension,” International Heart Journal, vol. 50, no. 4, pp. 501–512, 2009. View at Publisher · View at Google Scholar · View at Scopus
  66. J. D. Tugwood and C. T. Montague, “Biology and toxicology of PPARγ ligands,” Human and Experimental Toxicology, vol. 21, no. 8, pp. 429–437, 2002. View at Publisher · View at Google Scholar · View at Scopus
  67. R. W. Nesto, D. Bell, R. O. Bonow et al., “Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association,” Circulation, vol. 108, no. 23, pp. 2941–2948, 2003. View at Publisher · View at Google Scholar · View at Scopus
  68. H. Zhang, A. Zhang, D. E. Kohan, R. D. Nelson, F. J. Gonzalez, and T. Yang, “Collecting duct-specific deletion of peroxisome proliferator-activated receptor γ blocks thiazolidinedione-induced fluid retention,” Proceedings of the National Academy of Sciences of the United States of America, vol. 102, no. 26, pp. 9406–9411, 2005. View at Publisher · View at Google Scholar · View at Scopus
  69. W. J. Geese, W. Achanzar, C. Rubin et al., “Genetic and gene expression studies implicate renin and endothelin-1 in edema caused by peroxisome proliferator-activated receptor ? agonists,” Pharmacogenetics and Genomics, vol. 18, no. 10, pp. 903–910, 2008. View at Publisher · View at Google Scholar · View at Scopus
  70. P. A. Sarafidis and G. L. Bakris, “Protection of the kidney by thiazolidinediones: an assessment from bench to bedside,” Kidney International, vol. 70, no. 7, pp. 1223–1233, 2006. View at Publisher · View at Google Scholar · View at Scopus
  71. B. H. Chung, S. W. Lim, K. O. Ahn et al., “Protective effect of peroxisome proliferator activated receptor ? agonists on diabetic and non-diabetic renal diseases,” Nephrology, vol. 10, supplement 2, pp. S40–S43, 2005. View at Publisher · View at Google Scholar · View at Scopus
  72. E. Ritz, “Renal dysfunction as a novel risk factor: microalbuminuria and cardiovascular risk,” Kidney International, Supplement, vol. 67, no. 93, pp. S25–S28, 2005. View at Google Scholar · View at Scopus
  73. J. Weissgarten, S. Berman, S. Efrati, M. Rapoport, Z. Averbukh, and L. Feldman, “Apoptosis and proliferation of cultured mesangial cells isolated from kidneys of rosiglitazone-treated pregnant diabetic rats,” Nephrology Dialysis Transplantation, vol. 21, no. 5, pp. 1198–1204, 2006. View at Publisher · View at Google Scholar · View at Scopus
  74. A. Benigni, C. Zoja, S. Tomasoni et al., “Transcriptional regulation of nephrin gene by peroxisome proliferator-activated receptor-? agonist: molecular mechanism of the antiproteinuric effect of pioglitazone,” Journal of the American Society of Nephrology, vol. 17, no. 6, pp. 1624–1632, 2006. View at Publisher · View at Google Scholar · View at Scopus
  75. Z. Yousefipour, H. Hercule, L. Truong, A. Oyekan, and M. A. Newaz, “Ciglitazone, a peroxisome proliferator-activated receptor γ inducer, ameliorates renal preglomerular production and activity of angiotensin II and thromboxane A2 in glycerol-induced acute renal failure,” Journal of Pharmacology and Experimental Therapeutics, vol. 322, no. 2, pp. 461–468, 2007. View at Publisher · View at Google Scholar · View at Scopus
  76. T. Matsui, S. Yamagishi, S. Ueda et al., “Telmisartan, an angiotensin II type 1 receptor blocker, inhibits advanced glycation end-product (AGE)-induced monocyte chemoattractant protein-1 expression in mesangial cells through downregulation of receptor for AGEs via peroxisome proliferator-activated receptor-? activation,” Journal of International Medical Research, vol. 35, no. 4, pp. 482–489, 2007. View at Google Scholar · View at Scopus
  77. D. Watanabe, A. Tanabe, M. Naruse, S. Morikawa, T. Ezaki, and K. Takano, “Renoprotective effects of an angiotensin II receptor blocker in experimental model rats with hypertension and metabolic disorders,” Hypertension Research, vol. 32, no. 9, pp. 807–815, 2009. View at Publisher · View at Google Scholar · View at Scopus
  78. W. Arozal, K. Watanabe, P. T. Veeraveedu et al., “Effects of angiotensin receptor blocker on oxidative stress and cardio-renal function in streptozotocin-induced diabetic rats,” Biological and Pharmaceutical Bulletin, vol. 32, no. 8, pp. 1411–1416, 2009. View at Publisher · View at Google Scholar · View at Scopus
  79. R. Kalaitzidis and G. L. Bakris, “Effects of angiotensin II receptor blockers on diabetic nephropathy,” Journal of Hypertension, vol. 27, supplement 5, pp. S15–S21, 2009. View at Google Scholar
  80. M. Satoh, Y. Haruna, S. Fujimoto, T. Sasaki, and N. Kashihara, “Telmisartan improves endothelial dysfunction and renal autoregulation in Dahl salt-sensitive rats,” Hypertension Research, vol. 33, no. 2, pp. 135–142, 2010. View at Publisher · View at Google Scholar · View at Scopus
  81. G. R. Dagenais, H. C. Gerstein, R. Holman et al., “Effects of ramipril and rosiglitazone on cardiovascular and renal outcomes in people with impaired glucose tolerance or impaired fasting glucose: results of the Diabetes REduction Assessment with ramipril and rosiglitazone Medication (DREAM) trial,” Diabetes Care, vol. 31, pp. 1007–1014, 2008. View at Google Scholar
  82. E. Blessing, M. Preusch, R. Kranzhöfer et al., “Anti-atherosclerotic properties of telmisartan in advanced atherosclerotic lesions in apolipoprotein E deficient mice,” Atherosclerosis, vol. 199, no. 2, pp. 295–303, 2008. View at Publisher · View at Google Scholar · View at Scopus
  83. M. Newaz, K. Ranganna, L. D. Truong, and A. Oyekan, “Effect of peroxisome proliferator-activated receptor-α siRNA on hypertension and renal injury in the rat following nitric oxide withdrawal and high salt diet,” Journal of Hypertension, vol. 27, no. 11, pp. 2223–2231, 2009. View at Publisher · View at Google Scholar · View at Scopus
  84. M. F. B. Braga and L. A. Leiter, “Role of renin-angiotensin system blockade in patients with diabetes mellitus,” American Journal of Cardiology, vol. 104, no. 6, pp. 835–839, 2009. View at Publisher · View at Google Scholar · View at Scopus
  85. A. J. Scheen, “Renin-angiotensin system inhibition prevents type 2 diabetes mellitus—part 2: overview of physiological and biochemical mechanisms,” Diabetes and Metabolism, vol. 30, no. 6, pp. 498–505, 2004. View at Google Scholar · View at Scopus
  86. C. Guo, V. Ricchiuti, B. Q. Lian et al., “Mineralocorticoid receptor blockade reverses obesity-related changes in expression of adiponectin, peroxisome proliferator-activated receptor-?, and proinflammatory adipokines,” Circulation, vol. 117, no. 17, pp. 2253–2261, 2008. View at Publisher · View at Google Scholar · View at Scopus
  87. S. Zorad, J.-T. Dou, J. Benicky et al., “Long-term angiotensin II AT receptor inhibition produces adipose tissue hypotrophy accompanied by increased expression of adiponectin and PPAR?,” European Journal of Pharmacology, vol. 552, no. 1–3, pp. 112–122, 2006. View at Publisher · View at Google Scholar · View at Scopus
  88. A. Storka, E. Vojtassakova, M. Mueller et al., “Angiotensin inhibition stimulates PPAR? and the release of visfatin,” European Journal of Clinical Investigation, vol. 38, no. 11, pp. 820–826, 2008. View at Publisher · View at Google Scholar · View at Scopus
  89. F. Younis, N. Stern, R. Limor, Y. Oron, S. Zangen, and T. Rosenthal, “Telmisartan ameliorates hyperglycemia and metabolic profile in nonobese Cohen-Rosenthal diabetic hypertensive rats via peroxisome proliferator activator receptor-γ activation,” Metabolism. In press. View at Publisher · View at Google Scholar
  90. K. Nakaya, M. Ayaori, T. Hisada et al., “Telmisartan enhances cholesterol efflux from THP-1 macrophages by activating PPAR?,” Journal of Atherosclerosis and Thrombosis, vol. 14, no. 3, pp. 133–141, 2007. View at Google Scholar · View at Scopus
  91. J. Bosch, S. Yusuf, H. C. Gerstein et al., “Effect of ramipril on the incidence of diabetes,” The New England Journal of Medicine, vol. 355, no. 15, pp. 1551–1562, 2006. View at Publisher · View at Google Scholar · View at Scopus
  92. G. Derosa, E. Fogari, A. F. G. Cicero et al., “Blood pressure control and inflammatory markers in type 2 diabetic patients treated with pioglitazone or rosiglitazone and metformin,” Hypertension Research, vol. 30, no. 5, pp. 387–394, 2007. View at Publisher · View at Google Scholar · View at Scopus